Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | HTR1A | P08908 | 5/20 | 0.62 |
| ▸ | HTR7 | P34969 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8091444 | 0.88 | MEN1 (0.80) | MEN1KMT2AALDH1A1SMN1; SMN2HTR1A | |
| SCHEMBL16501806 | 0.86 | MEN1 (0.78) | MEN1KMT2AALDH1A1SMN1; SMN2HTR1A | |
| SCHEMBL17884894 | 0.82 | KMT2A (0.67) | MEN1KMT2AALDH1A1SMN1; SMN2HTR1A | |
| SCHEMBL30609744 | 0.82 | KMT2A (0.67) | MEN1KMT2AALDH1A1SMN1; SMN2HTR1A | |
| SCHEMBL10196665 | 0.81 | POLB (0.73) | ALDH1A1 | |
| SCHEMBL20708253 | 0.80 | MEN1 (0.60) | MEN1KMT2AALDH1A1SMN1; SMN2HTR1A | |
| SCHEMBL20306240 | 0.80 | AR (0.65) | MEN1KMT2AALDH1A1SMN1; SMN2HTR1A | |
| SCHEMBL4352910 | 0.79 | MEN1 (0.79) | MEN1KMT2AALDH1A1SMN1; SMN2HTR1A | |
| SCHEMBL9320601 | 0.78 | MEN1 (0.68) | MEN1KMT2AALDH1A1SMN1; SMN2HTR1A | |
| SCHEMBL4770262 | 0.78 | AKT1 (0.56) | HTR1AHTR7TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | MEN1 1807/4885KMT2A 41/4885ALDH1A1 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.